Pharmacokinetic evaluation and studies on the clinical efficacy of guar gum‐–based oral drug delivery systems of albendazole and albendazole‐β‐cyclodextrin for colon‐targeting in human volunteers

Abstract

Abstract The present investigation assessed the in vivo properties of the guar gum–based colon‐targeted matrix tablets of albendazole‐β‐cyclodextrin (KA), albendazole matrix tablet (GA), and an immediate‐release albendazole tablet (CA) in humans. A single oral dose was administered in healthy human volunteers and a completely randomized, two‐way, three‐period crossover design was adopted. The data were statistically analyzed and a value of P <0.05 was considered statistically significant. In healthy human volunteers, guar gum colon‐targeted tablets showed delayed t max and absorption time, decreased absorption rate constant, and unaltered t 1/2 indicating that albendazole is not released in stomach and small intestine, but is delivered to the colon, resulting in a slow absorption of the drug and making the drug available for local action in the colon. The increase in C max and AUC 0‐∞ of KA shows that the bioavailability of albendazole in humans could be definitely improved by complexing the drug with β‐cyclodextrin. Furthermore, an open, parallel, single‐blind clinical study was conducted in patient volunteers who had helminthiasis. Clinical studies showed that the guar gum colon‐targeted tablets could reduce eggs per gram faster than conventional tablets could, resulting in improved clinical symptoms, Hb content, and decreased total count as compared to conventional tablets of albendazole. The investigation shows that albendazole, when complexed with β‐cyclodextrin, improves in vivo bioavailability of the drug and colon targeting using guar gum ensures drug delivery in the colonic fluids, and therefore improves clinical efficacy in human beings with helminthiasis. Drug Dev. Res. 67:154–165, 2006. © 2006 Wiley‐Liss, Inc.